Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19127711 | 0.87 | DRD4 (0.36) | CYP1A2 | |
| SCHEMBL18554600 | 0.78 | CNR1 (0.42) | — | |
| SCHEMBL3057752 | 0.74 | KDM4E (0.50) | CYP1A2GRM4 | |
| SCHEMBL478887 | 0.74 | PDPK1 (0.54) | — | |
| SCHEMBL17387715 | 0.72 | PRMT5 (0.30) | — | |
| SCHEMBL1694765 | 0.71 | CYP1A2 (0.43) | CYP1A2 | |
| SCHEMBL2305274 | 0.71 | KDM4E (0.32) | — | |
| SCHEMBL18188335 | 0.71 | KDM4E (0.32) | — | |
| SCHEMBL5662185 | 0.71 | PDPK1 (0.36) | — | |
| SCHEMBL1195920 | 0.71 | PDPK1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-02 | — | — | US | claimed |
| EP-3194374-B1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-08-01 | — | — | EP | claimed |
| EP-3194374-A1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | Idorsia Pharmaceuticals Ltd (CH) | 2017-07-26 | — | — | EP | claimed |
| WO-2016041892-A1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-24 | — | — | WO | claimed |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-02 | — | — | US | disclosed |
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-15 | — | — | US | disclosed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | disclosed |
| EP-3194374-B1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-08-01 | — | — | EP | disclosed |
| EP-3194374-A1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | Idorsia Pharmaceuticals Ltd (CH) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016041892-A1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-24 | — | — | WO | disclosed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | disclosed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | CACNA1I, CACNA1E, CACNA1G | CYP1A2 581/4885GRM4 988/4885 |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CYP1A2 439/4885GRM4 3147/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | CYP1A2 439/4885GRM4 3147/4885 |
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CYP1A2 439/4885GRM4 3147/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CYP1A2 439/4885GRM4 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.